Literature DB >> 6861067

Early changes in human myocardial nuclei after doxorubicin.

B J Unverferth, R D Magorien, S P Balcerzak, C V Leier, D V Unverferth.   

Abstract

Ten nuclei from the endomyocardial biopsies for each of the following 32 patients were examined by electron microscopy: seven patients before and then four and 24 hours after treatment with first-dose doxorubicin; seven patients before and four and 24 hours after treatment with first-dose doxorubicin plus N-acetyl cysteine; nine patients with doxorubicin induced cardiomyopathy; and nine patients with idiopathic congestive cardiomyopathy. Five criteria were used to semiquantitatively compare nuclei and nucleoli from each group. The most dramatic changes in nuclear and nucleolar morphology were seen four hours after doxorubicin administration. Nucleoli were smaller, contracted or segregated and contained fewer fibrillar centers and a collapsed or fragmented nucleolonema. The addition of N-acetylcysteine to treatment did not alter these results. By 24 hours, nuclei had returned to the pre-treatment status. Long-term doxorubicin therapy produced increased chromatin clumping and slightly contracted nucleoli. The idiopathic congestive cardiomyopathic nuclei differed significantly from these doxorubicin cardiomyopathic nuclei in the decreased amount of chromatin clumping and the increase in fibrillar centers and nucleonema pattern. It is concluded from this study that: (1) doxorubicin markedly alters the morphology of the human myocardial nucleus and nucleolus four hours after treatment, but these changes diminish by 24 hours; (2) N-acetylcysteine treatment fails to prevent these changes; and (3) the nuclei and nucleoli of chronic doxorubicin-induced cardiomyopathy differ significantly from other congestive cardiomyopathies, but do resemble changes seen four hours after the first dose of doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861067     DOI: 10.1002/1097-0142(19830715)52:2<215::aid-cncr2820520206>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  NAD(P)H:quinone oxidoreductase 1 is induced by progesterone in cardiomyocytes.

Authors:  Stephen Morrissy; Joshua Strom; Sally Purdom-Dickinson; Qin M Chen
Journal:  Cardiovasc Toxicol       Date:  2012-06       Impact factor: 3.231

2.  Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits.

Authors:  N V Dimitrov; M B Hay; S Siew; D A Hudler; L J Charamella; D E Ullrey
Journal:  Am J Pathol       Date:  1987-02       Impact factor: 4.307

3.  Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.

Authors:  Brian A Van Tine; Angela C Hirbe; Peter Oppelt; Ashley E Frith; Richa Rathore; Joshua D Mitchell; Fei Wan; Shellie Berry; Michele Landeau; George A Heberton; John Gorcsan; Peter R Huntjens; Yoku Soyama; Justin M Vader; Jose A Alvarez-Cardona; Kathleen W Zhang; Daniel J Lenihan; Ronald J Krone
Journal:  Clin Cancer Res       Date:  2021-03-25       Impact factor: 12.531

4.  Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.

Authors:  Runyawan Chotenimitkhun; Ralph D'Agostino; Julia A Lawrence; Craig A Hamilton; Jennifer H Jordan; Sujethra Vasu; Timothy L Lash; Joseph Yeboah; David M Herrington; W Gregory Hundley
Journal:  Can J Cardiol       Date:  2014-11-26       Impact factor: 5.223

5.  The paradox of the first cycle of chemotherapy-transient improvement of contractility and diastolic function after the first cycle of anthracycline-based chemotherapy: a prospective clinical trial.

Authors:  Paweł Stachowiak; Andrzej Wojtarowicz; Marta Milchert-Leszczyńska; Krzysztof Safranow; Michał Falco; Robert Kaliszczak; Zdzisława Kornacewicz-Jach
Journal:  Oncotarget       Date:  2017-09-27

6.  Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes.

Authors:  Liqun Zhao; Baolin Zhang
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

7.  Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity.

Authors:  Jessica M Miller; Moustafa H Meki; Qinghui Ou; Sharon A George; Anna Gams; Riham R E Abouleisa; Xian-Liang Tang; Brooke M Ahern; Guruprasad A Giridharan; Ayman El-Baz; Bradford G Hill; Jonathan Satin; Daniel J Conklin; Javid Moslehi; Roberto Bolli; Alexandre J S Ribeiro; Igor R Efimov; Tamer M A Mohamed
Journal:  Toxicol Appl Pharmacol       Date:  2020-08-30       Impact factor: 4.460

8.  Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.

Authors:  Agnes Maillet; Kim Tan; Xiaoran Chai; Singh N Sadananda; Ashish Mehta; Jolene Ooi; Michael R Hayden; Mahmoud A Pouladi; Sujoy Ghosh; Winston Shim; Liam R Brunham
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

9.  The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity.

Authors:  Edoardo Lazzarini; Carolina Balbi; Paola Altieri; Ulrich Pfeffer; Elisa Gambini; Marco Canepa; Luigi Varesio; Maria Carla Bosco; Domenico Coviello; Giulio Pompilio; Claudio Brunelli; Ranieri Cancedda; Pietro Ameri; Sveva Bollini
Journal:  Sci Rep       Date:  2016-07-21       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.